SOURCE: World Street Fundamentals

November 07, 2011 09:00 ET

A Turn in Tide, Europe's New Deal - Research Report on Novartis AG (ADR) and SciClone Pharmaceuticals, Inc.

HONG KONG--(Marketwire - Nov 7, 2011) - Today, released its industry report highlighting Novartis AG (ADR) (NYSE: NVS) and SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN). Full fundamental and technical analysis is available at

Markets are starting to step in the right direction, with the European Financial Stability Facility (EFSF) increasing from $600 billion to $1.4 trillion, a significant move to strengthen the safety net in place for Europe's most troubled countries.

It is likely China and the IMF will contribute to the bailout fund, with Greece alone receiving $180 billion in fresh aid. The remainder of Greece's obligations were halved in the process, with private bondholders of Greek debt settling at 50% -- allowing banks to recapitalize at a healthy 9% reserve and bring Greece's debt burden down to 120% of GDP by 2020.

An important consideration is political commitment to this road map and probability of ongoing support for European Central Bank (ECB)'s recent deal. Currently the global community appears to be on point with ECB's initiative, an outlook that should be sufficient to support markets around current levels.

World Street Fundamentals has highlighted Novartis AG (ADR) for its current position within the healthcare industry. Novartis AG (Novartis) provides healthcare solutions. The Company's portfolio includes medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products. The Company operates in four divisions: pharmaceuticals, vaccines and diagnostics, sandoz, and consumer health. The entire report on Novartis AG (ADR) (NYSE: NVS) is available here:

World Street has featured SciClone Pharmaceuticals, Inc. for its development within the healthcare industry. SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company. It has a product portfolio of therapies for cancer and infectious diseases. SciClone has in-licensed two products that are part of this international commercial growth strategy, DC Bead and ondansetron RapidFilm. The entire report on SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is available here:

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets.

Contact Information